biologics

简明释义

英[ˌbaɪəʊˈlɒdʒɪks]美[baɪəˈlɑːdʒɪks]

n. 生物制剂

英英释义

单词用法

同义词

反义词

例句

1.Animals are sometimes used in the testing of drugs, vaccines and other biologics, and medical devices, mainly to determine the safety of the medical product.

有些时候测试药物，疫苗和其他生物制品及医疗器械需要使用动物，主要是为了检测医药产品的安全性。

2.Albumin fusion technology was a novel technology utilized to develop long-acting biologics.

血清白蛋白融合技术是一种开发长效重组蛋白药物的新技术。

3.FDA has placed consumer and industry members on advisory committees it consults concerning over-the-counter drugs, medical devices, and biologics.

美国食品和药品管理局在非处方药，医疗器械和生物制品领域，向包括消费者和产业界代表在内的咨询委员会进行咨询。

4.All subsequent systemic therapy, including biologics, is based on that premise.

随后的所有系统治疗，包括生物制剂，也将基于这一前提。

5.The Food and Drug Administration, however, lacks the legal ability to approve generic versions of biologics.

而食品和药物管理局缺乏相关的法律权能去批准生物药品的仿制。

6.Drugs recommended to be stopped before pregnancy include methotrexate and leflunomide, plus the biologics: anti-TNF agents, rituximab and abatacept.

怀孕前应终止使用的药物包括甲氨蝶呤、来氟米特和一些生物制剂包括抗肿瘤坏死因子制剂、利妥昔单抗和阿巴西普。

7.All of the current, FDA-approved HIV diagnostics are listed on the agency's Center for Biologics Evaluation and Research ( CBER) website, which is updated regularly.

目前，FDA批准的HIV检测都列在生物制品评估与研究机构中心的网站上，这些信息都会定期更新。

8.The rise of personalized medicine has increased the demand for biologics 生物制剂 tailored to individual patients.

个性化医疗的兴起增加了对针对个体患者定制的biologics 生物制剂的需求。

9.Researchers are exploring new biologics 生物制剂 that can improve cancer treatment outcomes.

研究人员正在探索新的biologics 生物制剂，以改善癌症治疗效果。

10.The approval process for biologics 生物制剂 is often more complex than for traditional drugs.

对于biologics 生物制剂的批准过程通常比传统药物更复杂。

11.The company specializes in the development of biologics 生物制剂 for treating autoimmune diseases.

该公司专注于开发用于治疗自身免疫疾病的biologics 生物制剂。

12.Many patients rely on biologics 生物制剂 to manage chronic inflammatory conditions.

许多患者依靠biologics 生物制剂来管理慢性炎症状况。

作文

In recent years, the field of medicine has witnessed remarkable advancements, particularly in the development and application of biologics. 生物制剂 are products derived from living organisms, including proteins, nucleic acids, or cells, that are used for therapeutic purposes. These innovative treatments have revolutionized how we approach various diseases, offering new hope to patients who previously had limited options. One of the most significant advantages of biologics 生物制剂 is their ability to target specific pathways in the body. Unlike traditional pharmaceuticals that often affect multiple systems indiscriminately, biologics 生物制剂 are designed to interact with particular molecules involved in disease processes. For example, monoclonal antibodies, a type of biologics 生物制剂, can be engineered to bind to specific antigens on cancer cells, marking them for destruction by the immune system. This precision not only enhances treatment efficacy but also minimizes side effects, making it a more favorable option for patients. Moreover, the versatility of biologics 生物制剂 extends beyond oncology. They play a crucial role in treating autoimmune diseases, such as rheumatoid arthritis and psoriasis, where they help modulate the immune response. By inhibiting specific inflammatory pathways, these therapies can significantly improve the quality of life for individuals suffering from chronic conditions. The manufacturing process of biologics 生物制剂 is also distinct and complex compared to traditional drugs. Producing these therapies involves intricate biotechnological methods, including cell culture and fermentation techniques. As a result, the production of biologics 生物制剂 requires stringent regulatory oversight to ensure safety, efficacy, and consistency. This complexity contributes to the higher cost associated with biologics 生物制剂, which can be a barrier to access for many patients. However, the benefits often outweigh the costs, as these treatments can lead to significant health improvements and reduce long-term healthcare expenses. Despite their promise, the use of biologics 生物制剂 is not without challenges. Some patients may experience adverse reactions, and there is a risk of developing antibodies against the treatment, which can diminish its effectiveness. Additionally, the long-term effects of these therapies are still being studied, necessitating ongoing research and monitoring. In conclusion, biologics 生物制剂 represent a groundbreaking advancement in the field of medicine, providing targeted and effective treatment options for various diseases. Their ability to specifically address the underlying mechanisms of illness has changed the landscape of healthcare, offering new hope to countless patients. As research continues to evolve, we can anticipate even more innovative biologics 生物制剂 on the horizon, paving the way for a future where personalized medicine becomes the norm rather than the exception. The journey of biologics 生物制剂 is just beginning, and its potential is limitless.

近年来，医学领域见证了显著的进步，特别是在生物制剂的开发和应用方面。生物制剂是从生物体中提取的产品，包括用于治疗目的的蛋白质、核酸或细胞。这些创新疗法彻底改变了我们对各种疾病的处理方式，为之前选择有限的患者带来了新的希望。生物制剂的一个重要优势是它们能够针对身体中的特定通路。与传统药物往往无差别地影响多个系统不同，生物制剂旨在与参与疾病过程的特定分子相互作用。例如，单克隆抗体作为一种生物制剂，可以被设计为与癌细胞上的特定抗原结合，从而标记它们被免疫系统摧毁。这种精准不仅提高了治疗效果，还最小化了副作用，使其成为患者更有利的选择。此外，生物制剂的多样性不仅限于肿瘤学。它们在治疗自身免疫性疾病（如类风湿性关节炎和银屑病）中发挥着至关重要的作用，帮助调节免疫反应。通过抑制特定的炎症通路，这些疗法可以显著改善慢性病患者的生活质量。与传统药物相比，生物制剂的生产过程也是独特而复杂的。生产这些疗法涉及复杂的生物技术方法，包括细胞培养和发酵技术。因此，生物制剂的生产需要严格的监管，以确保安全性、有效性和一致性。这种复杂性导致了与生物制剂相关的较高成本，这可能成为许多患者获取的障碍。然而，益处往往超过成本，因为这些治疗可以显著改善健康状况并减少长期医疗费用。尽管前景广阔，生物制剂的使用并非没有挑战。一些患者可能会经历不良反应，并且存在产生抗体对抗治疗的风险，这可能会降低其有效性。此外，这些疗法的长期效果仍在研究中，需要持续的研究和监测。总之，生物制剂代表了医学领域的一项突破性进展，为各种疾病提供了针对性和有效的治疗选择。它们能够具体解决疾病的根本机制，改变了医疗保健的格局，为无数患者带来了新的希望。随着研究的不断发展，我们可以期待更多创新的生物制剂出现在未来，铺平个性化医疗成为常态而非例外的道路。生物制剂的旅程才刚刚开始，其潜力是无限的。